Subscribe to Newsletter

Drug Discovery

Discovery & Development Drug Discovery

Science Fiction Comes to Life

| Rob Coker | 3 min read

Researchers are working on ways to introduce nanoscale artificial life-forms to viruses with the aim of mimicking the human immune system

Discovery & Development Drug Discovery

New Antibiotic on the Block

| Jamie Irvine | 2 min read

New antibiotic candidate Clovibactin eliminates bacteria without developing resistance

Discovery & Development Drug Discovery

The Chance to Stop – or Even Prevent – Neurodegenerative Diseases

| Andrea Pfeifer | 7 min read

Will our generation be the last to face untreatable Alzheimer’s disease? With predictive biomarkers and active immunotherapies, just maybe.

Discovery & Development Drug Discovery

The Evolution of HIV/AIDS Treatment

| Jamie Irvine | 6 min read

In light of cabotegravir’s positive opinion for sexually acquired HIV-1, I wanted to explore the history and politics of HIV/AIDS drug development

Discovery & Development Drug Discovery

Nobel Prize for mRNA COVID-19 Vaccine Technology

| Stephanie Vine | 7 min read

Katalin Karikó and Drew Weissman win prestigious prize for persevering in a field that many ignored.

Business & Regulation Profession

The Journey of Founding a Company

| Stacy Blain | 8 min read

Lessons learned in starting up a company – and navigating an industry dominated by men.

Manufacture Bioprocessing - Upstream & Downstream

Less Patience, More Patients

| 4 min read

Sitting Down With Dick Sundh, General Manager, Kite Pharma

Discovery & Development Drug Discovery

The FLEET of Hope

| Robert H Cichewicz | 3 min read

Fungal infections and antifungal resistance are a significant problem; here’s one approach to consider

Discovery & Development Drug Discovery

Meet an AI Model that Predicts Teratogenicity

| Jamie Irvine | 3 min read

Researchers demonstrate that complex data analysis paired with artificial intelligence can predict additional causes of Teratogenicity

Discovery & Development Drug Discovery

CRISPR With Caution

| Rob Coker | 3 min read

Deputy editor Rob Coker recalls his trip to the labs of Caszyme, Vilnius, where he spoke with CEO Monika Paule about the potential of genome editing

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register